Zentalis Pharmaceuticals (ZNTL) Competitors $3.47 -0.48 (-12.15%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZNTL vs. CYRX, PRLD, IRWD, IGMS, PAHC, IMTX, SEPN, COLL, CRGX, and PRTAShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Cryoport (CYRX), Prelude Therapeutics (PRLD), Ironwood Pharmaceuticals (IRWD), IGM Biosciences (IGMS), Phibro Animal Health (PAHC), Immatics (IMTX), Septerna (SEPN), Collegium Pharmaceutical (COLL), CARGO Therapeutics (CRGX), and Prothena (PRTA). Zentalis Pharmaceuticals vs. Cryoport Prelude Therapeutics Ironwood Pharmaceuticals IGM Biosciences Phibro Animal Health Immatics Septerna Collegium Pharmaceutical CARGO Therapeutics Prothena Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends. Do analysts rate ZNTL or CYRX? Zentalis Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 188.18%. Cryoport has a consensus target price of $12.50, indicating a potential upside of 78.83%. Given Zentalis Pharmaceuticals' higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Cryoport 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, ZNTL or CYRX? Zentalis Pharmaceuticals has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Which has better valuation & earnings, ZNTL or CYRX? Cryoport has higher revenue and earnings than Zentalis Pharmaceuticals. Cryoport is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis PharmaceuticalsN/AN/A-$292.19M-$2.49-1.39Cryoport$233.26M1.48-$99.59M-$3.38-2.07 Does the MarketBeat Community favor ZNTL or CYRX? Cryoport received 182 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 64.96% of users gave Cryoport an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZentalis PharmaceuticalsOutperform Votes5963.44% Underperform Votes3436.56% CryoportOutperform Votes24164.96% Underperform Votes13035.04% Is ZNTL or CYRX more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -43.91% -34.96% Cryoport -70.08%-13.35%-6.43% Do insiders & institutionals have more ownership in ZNTL or CYRX? 92.9% of Cryoport shares are held by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 10.1% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor ZNTL or CYRX? In the previous week, Zentalis Pharmaceuticals had 14 more articles in the media than Cryoport. MarketBeat recorded 20 mentions for Zentalis Pharmaceuticals and 6 mentions for Cryoport. Cryoport's average media sentiment score of 0.64 beat Zentalis Pharmaceuticals' score of 0.62 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cryoport 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCryoport beats Zentalis Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$247.29M$6.48B$5.12B$8.72BDividend YieldN/A8.13%5.18%4.07%P/E Ratio-1.395.6972.8114.16Price / SalesN/A349.551,250.2081.71Price / CashN/A53.3440.7036.03Price / Book0.709.606.455.94Net Income-$292.19M$154.43M$119.73M$225.73M7 Day Performance-12.37%-9.46%-5.13%-1.34%1 Month Performance15.67%-7.27%-2.71%1.15%1 Year Performance-69.43%28.13%31.08%24.02% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.454 of 5 stars$3.47-12.2%$10.00+188.2%-69.1%$247.29MN/A-1.39160Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCYRXCryoport2.7161 of 5 stars$8.05+0.2%N/A-47.7%$397.75M$233.26M-2.381,170PRLDPrelude Therapeutics2.7819 of 5 stars$1.15-3.4%N/A-69.4%$63.29MN/A-0.65120Short Interest ↑IRWDIronwood Pharmaceuticals4.2073 of 5 stars$4.34-9.2%N/A-55.4%$693.27M$442.73M-144.67220Analyst DowngradeShort Interest ↓IGMSIGM Biosciences4.6905 of 5 stars$11.80-8.4%N/A+64.4%$699.98M$2.13M-3.24190Earnings ReportShort Interest ↓PAHCPhibro Animal Health4.3687 of 5 stars$25.56+0.0%N/A+132.3%$1.04B$1.02B59.441,940Analyst UpgradeIMTXImmatics2.3143 of 5 stars$8.57-5.2%N/A-3.9%$1.02B$58.44M-9.63260Short Interest ↓SEPNSepternaN/A$24.00-5.7%N/AN/A$1.01B$838,000.000.00N/APositive NewsCOLLCollegium Pharmaceutical4.1071 of 5 stars$31.06-3.5%N/A+17.8%$1.00B$566.77M13.39210CRGXCARGO Therapeutics1.7566 of 5 stars$21.33-3.0%N/A+8.5%$979.15MN/A-0.42116Earnings ReportAnalyst ForecastNews CoveragePRTAProthena1.7428 of 5 stars$17.53-3.0%N/A-59.4%$942.76M$217.25M-17.53173Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies CYRX Competitors PRLD Competitors IRWD Competitors IGMS Competitors PAHC Competitors IMTX Competitors SEPN Competitors COLL Competitors CRGX Competitors PRTA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZNTL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts